All articles by Phillip Broadwith – Page 9
-
-
OpinionAugmented intelligence
Robots will increasingly work alongside humans to solve complex problems
-
BusinessMallinckrodt settles US opioid lawsuit
Firm will pay $35m over allegations it failed to report suspicious orders of controlled substances
-
BusinessEU to investigate Merck KGaA’s merger with Sigma–Aldrich
Commission says Merck failed to disclose a crucial research project
-
BusinessCelgene and BeiGene agree cancer partnership
Immuno-oncology deal sees firms exchange licensing rights for antibody drugs
-
OpinionWhat's holding back continuous manufacturing?
Despite manay advantages, the move to flow chemistry in fine and speciality chemicals is slow
-
BusinessGM corn growers win US lawsuit against Syngenta
Kansas jury awards over $217m damages to farmers in the first of eight trials
-
BusinessJ&J licenses Protagonist’s inflammatory bowel peptide
Potential first-in-class treatment is just about to enter clinical trials
-
BusinessExplosion kills 10 at Chinese petrochemical plant
Nine others injured when gas tanker exploded in loading area
-
BusinessIneos expands North Sea oil and gas operations
Purchase of Danish Dong Energy and BP’s Forties pipeline will feed Grangemouth refinery
-
OpinionDrug pricing must be more transparent
Pricing is a complex issue - how can we make it clearer?
-
BusinessSeattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
-
BusinessPatheon buyout brings Thermo into contract manufacturing
$7.2bn deal expands Thermo Fisher’s laboratory products and services segment
-
BusinessAvantor to buy VWR for $6.4bn
Deal continues trend of consolidation in laboratory supplies sector
-
BusinessBP to sell Chinese joint venture stake to Sinopec
Oil giant retains significant investment in China, but is shifting focus
-
BusinessChina approves BMS’s hepatitis C drugs
Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved
-
OpinionBuilding business across borders
Internationality is here to stay. Companies need to capitalise on it
-
BusinessFresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
-
BusinessJob cuts at Amgen, Takeda and Vertex
Takeda reorganising following Ariad takeover, while Amgen and Vertex move staff to Cambridge and San Francisco hubs
-
BusinessAnalytical data heads to the cloud
Many manufacturers were launching software instead of instruments at Pittcon